Formulation and evaluation of atorvastatin calcium niosomes

Neha Rani 1, Rupali Rana 1, Reena Thakur 1, Shivali Singla 1,* and Sachin Goyal 2

1 Department of Pharmaceutics, Himalayan Institute of Pharmacy, Kala-Amb, H.P., India.

2 Department of Phamacology, Himalayan Institute of Pharmacy, Kala-Amb, H.P., India.

 

Research Article
International Journal of Science and Research Archive, 2021, 02(01), 116-124.
Article DOI: 10.30574/ijsra.2021.2.1.0028
Publication history: 
Received on 13 January 2021; revised on 15 February 2021; accepted on 17 February 2021
 
Abstract: 
Atorvastatin calcium is a HMG-CoA reductase inhibitor used for the treatment of hyperlipidaemia. It has oral bioavailability of ≤12 %. It also undergoes high first pass metabolism. It is highly soluble in acidic pH and absorbed more in the upper part of the gastrointestinal tract. In order, to improve the absorption and its oral bioavailability, niosomes of Atorvastatin calcium have been formulated and evaluated on different parameters. Niosomes play an increasingly important role in drug delivery as they can reduce toxicity and 000000000modify pharmacokinetic and bio-availability. Niosomes formulations of Atorvastatin calcium were successfully developed by thin film hydration technique using nonionic surfactant i.e. Span 40, Span 60 Span 80, Tween 20, Tween 40, Tween 80 and cholesterol at different concentrations. The formulations were evaluated for size, shape, and entrapment efficiency. In-vitro release and stability studies also performed.  Results indicated that Niosomes were prepared succesfully work as promising drug carriers and promising drug delivery module.
 
Keywords: 
Atorvastatin calcium; Niosomes; Surfactants; Thin film hydration technique; In-vitro release, Stability studies
 
Full text article in PDF: 
Copyright information: 

Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0